# Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

> **NCT07465718** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Orphalan** · enrollment: 38 (estimated)

## Conditions studied

- Wilson's Disease

## Interventions

- **DRUG:** TETA 4HCl formulation
- **DRUG:** D-Penicillamine

## Key facts

- **NCT ID:** NCT07465718
- **Lead sponsor:** Orphalan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465718, "Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07465718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*